AI Today
AI Project Management in the Pharmaceutical Industry – with Sumathi Arcot
Why It Matters
Pharma companies face intense regulatory scrutiny and high‑stakes outcomes, making disciplined AI project management essential for safety and compliance. By showcasing a structured, governance‑centric framework, the episode offers practitioners a roadmap to deliver AI value quickly without sacrificing rigor, a timely insight as AI adoption accelerates across life sciences.
Key Takeaways
- •CPM AI certification enforces business-first AI governance in pharma.
- •Lean‑Agile practices create rapid, transparent AI prototyping and delivery.
- •Phase 1 business understanding and Phase 2 data understanding drive success.
- •Built‑in go/no‑go gates de‑risk high‑stakes AI projects.
- •CPM AI artifacts align stakeholder perception with measurable AI value.
Pulse Analysis
In this episode, Sumathi Arkad, Lean‑Agile Transformation Lead at AstraZeneca, explains why she pursued the PMI‑CPM AI certification and how it reshapes AI project management in the pharmaceutical sector. She emphasizes a business‑first mindset, where AI is treated as a governed product from day one, complete with auditability, compliance checkpoints, and clear success criteria. This approach dovetails with the highly regulated environment of life sciences, ensuring that every initiative meets privacy, security, and ethical standards while delivering measurable patient‑centric outcomes.
Arkady walks through the six‑phase CPM AI methodology, highlighting that Phase 1 (business understanding) and Phase 2 (data understanding) are the most critical. By establishing a solid problem statement, KPI framework, and data readiness early, teams avoid costly rework and reduce hallucination risks in model development. The built‑in go/no‑go traffic‑light assessment provides a structured risk‑mitigation gate, separating low‑risk pilots from high‑stakes deployments. Lean‑Agile practices further accelerate prototyping, enable rapid feedback loops, and embed bias checks, explainability, and continuous monitoring—key ingredients for trustworthy AI in pharma.
Finally, the conversation links CPM AI to PMI’s M‑O‑R‑E framework, showing how transparent artifacts—problem statements, experiment readouts, and KPI dashboards—shape stakeholder perception and close the gap between delivery and perceived value. By communicating evidence‑backed progress at each lifecycle stage, project leaders turn abstract AI concepts into concrete, patient‑focused value propositions. This alignment not only satisfies regulatory demands but also drives strategic leadership, positioning AI as a catalyst for broader transformation across AstraZeneca’s oncology and rare‑disease units.
Episode Description
In this episode of AI Today, host Kathleen Walch sits down with Sumathi Arcot, Project Director for Lean Agile Transformation in AstraZeneca’s U.S. Oncology Business Unit, for a candid conversation on what it really takes to manage AI responsibly in one of the world’s most regulated industries.
Sumathi shares how the CPMAI methodology fundamentally shifted her perspective on AI, from something experimental and exploratory to a product discipline with defined outcomes, built-in governance, and clear success criteria from day one. In a pharma environment shaped by strict compliance requirements, she explains how CPMAI doesn’t slow innovation—it enables it—by aligning seamlessly with privacy impact assessments, third‑party risk reviews, and regulatory expectations.
Drawing on a real-world patient value impact analysis project in the rare diseases space, Sumathi highlights how CPMAI’s six phases—especially Phase I: Business Understanding and Phase II: Data Understanding—help teams focus on the right problem before model development begins. She also connects CPMAI to PMI’s M.O.R.E. vision, explaining how structured artifacts, KPIs, and go/no-go checkpoints help project managers move beyond delivery to value especially when navigating AI initiatives with diverse, risk-aware stakeholders.
You’ll hear insights on:
How CPMAI transforms AI experiments into governed, auditable products
Why Business Understanding is critical in AI initiatives
How pharma compliance aligns to CPMAI checkpoints
How the PMI M.O.R.E. vision helps project managers communicate AI value
What agentic AI and human‑in‑the‑loop leadership looks like in the years ahead
Whether you’re a project manager, transformation leader, or AI practitioner, this episode offers practical lessons for leading AI initiatives where the stakes and the scrutiny are high.
Comments
Want to join the conversation?
Loading comments...